Salute e Benessere

Philips joins Optum Healthcare’s network as a preferred provider in the USA

Philips’ ambulatory and diagnostic solutions and services are now available to 3.4 million Optum policyholders for enhanced outpatient cardiac monitoring Amsterdam, the Netherlands – Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has entered a national partnership in the USA with Optum Healthcare. The inclusion of Philips’Mobile Cardiac Telemetry(MCOT) and Philips Extended Holter (ePatch) in the network is designed to enable...
Nasdaq GlobeNewswire
25/09/2025

Leo Cancer Care and Xploro Unveil Statue Quest, a Game Designed to Support Young…

That's why Leo Cancer Care, a company developing radiation therapy solutions with its innovative upright approach, has partnered with Xploro, a leading patient education platform, to create a fun, interactive, and educational tool designed specifically for children preparing for upright cancer treatment in the future. Leo Cancer Care's solutions are in development, with first patient treatments expected later this year. Because making radiation therapy more human is central to their...
PR Newswire
25/09/2025

/C O R R E C T I O N -- Economist Impact/

Members of the media are invited to register here. Members of the media are invited toregister here. SINGAPORE , Sept. 25, 2025 /PRNewswire/ -- Convening onOctober 16that the Four Seasons Hotel, the 5th edition Future of Health Asia will bring together 500 senior leaders from healthcare, government and patient advocacy to examine the impact of rising technological disruptions, rising pressure of chronic diseases and global economic uncertainty. TheAsia-Pacific's...
PR Newswire
25/09/2025

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

TLSA ) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501. There has been heightened industry activity in the IL-6 pathway space, underscored by Novartis’ recent acquisition of Tourmaline Bio for approximately $1.4 billion. Tiziana will pursue non-dilutive funding strategies for the development of TZLS-501 while continuing to advance intranasal foralumab as its lead program.TZLS-501 is a...
Nasdaq GlobeNewswire
25/09/2025

Numab Therapeutics Achieves Milestone in Collaboration with Boehringer Ingelheim

Numab to receive first milestone paymentBoehringer Ingelheim has advanced its novel tumor antigen targeting T cell engager resulting from a collaboration with Numab into preclinical development HORGEN, Switzerland, Sept.25, 2025(GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today that Boehringer Ingelheim has advanced its novel T cell engager for the...
Nasdaq GlobeNewswire
25/09/2025

Cosmos Health Expands Order Book with Contract Manufacturing Agreement with…

Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”), has signed a contract manufacturing agreement with Medical Pharmaquality S.A. for MYCOFAGYL® pessaries, further expanding its pipeline of pharmaceutical products.Under the terms of the agreement, Cana will manufacture MYCOFAGYL®, a combination of Metronidazole (500mg)...
Nasdaq GlobeNewswire
25/09/2025

Zifo's AI Blueprints for Clinical Research Honored in CDISC Challenge

The AI Innovation Challenge, hosted by CDISC -- the global body that creates standards to make clinical research data easier to collect, share, and understand -- recognizes innovative solutions that leverage AI and CDISC standards to address key pain points in the clinical research landscape. The AI Innovation Challenge, hosted by CDISC -- the global body that creates standards to make clinical research data easier to collect, share, and understand-- recognizes innovative solutions that...
PR Newswire
25/09/2025

New Publication Urges Fashion Leaders to Accelerate Action at Mid-Decade Turning…

The updated agenda urges executives to take action according to its long-standing five-priority sustainability framework - Respectful and Secure Work Environments, Better Wage Systems, Resource Stewardship, Smart Material Choices, and Circular Systems. For the first time, the 2025 edition introduces Priority Accelerators: Innovation, Capital, Courage, Incentives, and Regulation. These build on the themes discussed at Global Fashion Summit: Copenhagen Edition this year, positioned as critical…
PR Newswire
25/09/2025

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible for development, regulatory and sales milestone payments with a potential value of up to $592 million, as well as royalties on salesMSD retains an option for a second vaccine candidate, EVX-B2, for which the evaluation period is extended with a...
Nasdaq GlobeNewswire
25/09/2025

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy…

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s diseaseACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polyclonal response...
Nasdaq GlobeNewswire
25/09/2025

Veterans Backing Veterans Through Service-Related Injuries

Unlike many other organisations in the sector, Veterans for Veterans was founded by former armed forces personnel who understand first-hand the long-term impact of hearing injuries. They have quickly grown in response to demand, with more and more veterans now coming forward for support with a range of service-related injuries. Beyond supporting claims, Veterans for Veterans provides the kind of guidance and solidarity that many feel was missing when they left the armed forces...
PR Newswire
25/09/2025

ZINZINO AB (PUBL.): ZINZINO ACQUIRES TRUVY TO INCREASE DISTRIBUTION CAPACITY IN…

Truvy is a global direct sales company in the health segment, operating in North America, Latin America, and South Korea. Its brand portfolio offers a range of innovative products in the areas of health and weight loss. Truvy is a global direct sales company in the health segment, operating inNorth America,Latin America, and South Korea. Its brand portfolio offers a range of innovative products in the areas of health and weight loss. The business has a total annual turnover of...
PR Newswire
25/09/2025

Lonza's Synaffix Collaborates with Qurient Therapeutics to Enable Development of…

The collaboration aims to develop a dual-payload ADC consisting of Synaffix's exatecan-based technology and Qurient's CDK7 inhibitor, aiming to target unmet medical needs in solid tumors. Under the terms of the agreement, Qurient will gain access to Lonza's clinical-stage, site-specific ADC technology platform powered by Synaffix services including GlycoConnect® antibody conjugation, HydraSpace® polar spacer, and exatecan-based linker-payload technologies, as well as Lonza's market-leading…
PR Newswire
25/09/2025

Sky Labs Launches CART BP, a Ring-Type Cuffless Blood Pressure Monitor

Worn on the finger, CART BP enables 24-hour blood pressure monitoring, including during sleep. The device has been approved by Korea's Ministry of Food and Drug Safety (MFDS) and was developed based on the clinically validated technology of CART BP pro, Sky Labs' professional model adopted by hospitals as an ambulatory blood pressure monitoring (ABPM) device. Worn on the finger, CART BP enables 24-hour blood pressure monitoring, including during sleep. The device has been approved by Korea's...
PR Newswire
25/09/2025

Implantica steps up to close the treatment gap with RefluxStop® as main device…

1LINX™ is a trademark of Torax Medical Inc. 1 LINX™ is a trademark of Torax Medical Inc. For further information, please contact: Nicole Pehrsson, Chief Corporate Affairs Officer Telephone (CH): +41 (0)79 335 09 [email protected] Implantica is listed on Nasdaq First North Premier Growth Market inStockholm. The company's Certified Adviser is FNCA Sweden AB,[email protected] The information was sent for publication, through the agency of the contact person set...
PR Newswire
25/09/2025

KLEA HOLDING (ex VISIOMED GROUP) : Klea Holding repurchases the remaining PARK…

Paris, 25 September 2025 KLEA HOLDING (FR0013481835 – ALKLH), a group focused on the acquisition, development and digital transformation of companies in various sectors, announces that it has repurchased the 22,831,050 PARK warrants (BSA) still in circulation for a total amount of €1,278,539 with a view to cancelling them, thereby avoiding any risk of future dilution…
Actusnews Wire
25/09/2025

Basilea awarded BARDA contract for the development of novel oral phase 3-ready…

- Total non-dilutive funding of up to USD 159 million upon completion of predefined milestones, including near-term committed funding of USD 6 million Ad hoc announcement pursuant to Art. 53 LRAllschwil, Switzerland, September 25, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development...
Nasdaq GlobeNewswire
25/09/2025

Santhera Provides Update on Convertible Bond Issued on 23 September 2025

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, September 25, 2025 –Santhera Pharmaceuticals (SIX: SANN) today provides the following update regarding its convertible bond announced on 23 September 2025: Details:The conversion price has been set at CHF 13.5446, representing a 10% premium to the volume-weighted average price (VWAP) of Santhera’s shares on 23 September 2025. The coupon is 7%, reflecting a reduction compared with the previous bond.The aggregate...
Nasdaq GlobeNewswire
25/09/2025

Press release: Sequana Medical announces H1 2025 results and provides business…

Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP “top-up” reimbursement; On track for at least 70 US commercial alfapump implants during “Soft Launch” – “Full Launch” on track for Q2 2026Debt reduction of EUR 2 million through partial conversion of Kreos loan and 2025 convertible loanTotal liquidity position of EUR 7.3 million as per 30 June 2025 ...
Nasdaq GlobeNewswire
25/09/2025

Fagron announces the acquisition of UCP in North America and FDA inspection…

Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 25 September 2025 – 7:00 AM CET Fagron announces the acquisition of UCP in North America and FDA inspection updateFagron, the leading global player in pharmaceutical compounding, is pleased to announce a strategic acquisition that will significantly reinforce its presence in North America. The company has signed the acquisition of University Compounding Pharmacy (UCP), a 503A pharmaceutical...
Nasdaq GlobeNewswire
25/09/2025

H1 25 Results Confirm the Relevance of Roquette’s Strategy

H1 25 Results Confirm the Relevance of Roquette’s StrategyRoquette outperforms its key markets, delivering solid H1 results in current complex market conditions.Successful completion of the acquisition of IFF Pharma Solutions 1 and implementation of a new organization with two complementary Business Groups 2.+4% turnover growth to €2,371 million (-3% Like-For-Like basis, LFL 3 ) and +18% EBITDA increase to €294 million (-1% LFL), supported by a favorable mix effect...
Nasdaq GlobeNewswire
25/09/2025

Moderate-to-Severe Acute Pain Market Anticipates Impressive Growth Trajectory at…

Moderate-to-Severe Acute Pain Market Summary Moderate-to-Severe Acute Pain Market Summary Discover which therapies are expected to grab the major moderate-to-severe acute pain treatment market share @Moderate-to-Severe Acute Pain Market Report Key Factors Driving the Moderate-to-Severe Acute Pain Market Growing Moderate to Severe Acute Pain Incidence The total number of incident cases of moderate-to-severe acute pain in the 7MM were around180 millionin 2024...
PR Newswire
24/09/2025

uniQure Announces $200 Million Proposed Public Offering

Leerink Partners, Stifel, Van Lanschot Kempen, and Guggenheim Securities are acting as bookrunning managers for the proposed offering.The securities described above are being offered by uniQure pursuant to its automatically effective shelf registration statement on Form S-3 (File No. 333-284168) filed with the U.S. Securities Exchange Commission (the “SEC”) on January 7, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the...
Nasdaq GlobeNewswire
24/09/2025

Inventiva to Host Analyst and Investor Event on October 8, 2025

Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026Three renowned international experts and a patient representative will highlight key trends shaping the MASH treatment landscapeDaix (France), New York City (New York, United States), September 24, 2025 –Inventiva(Euronext Paris and NASDAQ:IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on...
Nasdaq GlobeNewswire
24/09/2025
Altri  Comunicati